enGene Holdings Inc. (ENGN), a clinical-stage genetic medicines company, announced Monday the appointment of Joan Connolly as Chief Technology Officer and member of the corporate leadership team.
In addition, enGene Co-Founder and former CTO, Anthony Cheung, will transition to the role of Chief Scientific Officer, succeeding James Sullivan.
Connolly holds more than 30 years experience across CMC development for large and small molecules, manufacturing management, regulatory filings, and product commercialization, as well as supply chain, logistics and sourcing, and procurement.
In her most recent role, Connolly served as Chief Technology Officer of Albireo Pharma, Inc. Prior to Albireo, she held senior roles at Stemline Therapeutics, Inc., ImClone Systems Inc., and Bristol-Myers Squibb.
Ron Cooper, Chief Executive Officer of enGene said, "She brings significant experience in managing the technical operations required to drive a late-stage clinical asset through to commercialization, which will be critical as we complete the pivotal portion of the LEGEND study of detalimogene and anticipate filing our BLA in mid-2026."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.